Indaptus Therapeutics faces a precarious outlook as its clinical-stage bacterial platform development continues to drive significant quarterly operating losses, reaching $8.2 million in 2025Q4. The company lacks commercial revenue to offset these expenditures,...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.02+98.7% vs -$1.57 | — vs — |
Q2 2026 May 15, 2026 | -$0.23+87.7% vs -$1.87 | — vs — |
Q2 2026 Mar 17, 2026 | -$3.10+28.9% vs -$4.36 | — vs — |
Q4 2025 Nov 12, 2025 | -$2.98+28.5% vs -$4.17 | — vs — |
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update.
Benchmark INDP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Indaptus Therapeutics, Inc. (INDP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.85 | $214.84M | -0.09 | — | — | -587.59% | — | |
| $39.57 | $8.17B | -14.29 | — | -7585.86% | -69.59% | — | |
| $116.47 | $9.58B | -31.56 | -16.72% | -285.41% | -21.5% | — | |
| $29.06 | $3.65B | -8.83 | -4.26% | -386.32% | -87.98% | — | |
| $55.74 | $8.53B | 20.12 | 87.32% | 55.22% | 72.3% | — | |
| $3.23 | $231.09M | -2.29 | — | — | -39.64% | — |
Indaptus Therapeutics, Inc. (INDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Indaptus Therapeutics, Inc. (INDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 24, 2026·SEC
Jun 5, 2026·SEC
Get notified when INDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Indaptus Therapeutics, Inc. (INDP) stock FAQ — growth, dividends, profitability & financials explained
Indaptus Therapeutics, Inc. (INDP) reported a net loss of $15.4M for fiscal year 2025.
Indaptus Therapeutics, Inc. (INDP) has a return on equity (ROE) of -587.6%. Negative ROE indicates the company is unprofitable.
Indaptus Therapeutics, Inc. (INDP) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.
